One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration

IF 5.7 Q1 OPHTHALMOLOGY

Ophthalmology. Retina Pub Date : 2025-09-01 DOI:10.1016/j.oret.2025.03.015

Gabriela Grimaldi MD , Aude Ambresin MD , Isabel B. Pfister PhD , Christin Schild PhD , Christina Plasencia MD , Katja Hatz MD, PhD , Richard Stillenmunkes MD , Marion R. Munk MD , Arianna Paris MD , Moreno Menghini MD , Dmitri Artemiev MD , Andreas Ebneter MD, PhD , Jennifer Cattaneo MD , Eva C. de Oliveira Figueiredo PhD , Chiara M. Eandi MD, PhD , Jacqueline Fröhlich MD , Nicolas Feltgen MD, PhD , Tahm Spitznagel MD , Gábor Márk Somfai MD, PhD , Mariano Cozzi MD , Justus G. Garweg MD, PhD

{"title":"One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration","authors":"Gabriela Grimaldi MD , Aude Ambresin MD , Isabel B. Pfister PhD , Christin Schild PhD , Christina Plasencia MD , Katja Hatz MD, PhD , Richard Stillenmunkes MD , Marion R. Munk MD , Arianna Paris MD , Moreno Menghini MD , Dmitri Artemiev MD , Andreas Ebneter MD, PhD , Jennifer Cattaneo MD , Eva C. de Oliveira Figueiredo PhD , Chiara M. Eandi MD, PhD , Jacqueline Fröhlich MD , Nicolas Feltgen MD, PhD , Tahm Spitznagel MD , Gábor Márk Somfai MD, PhD , Mariano Cozzi MD , Justus G. Garweg MD, PhD","doi":"10.1016/j.oret.2025.03.015","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pretreated neovascular age-related macular degeneration (nAMD).</div></div><div><h3>Design</h3><div>Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.</div></div><div><h3>Subjects</h3><div>We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-VEGF therapy and followed for a minimum of 12 months between May 1, 2022, and October 30, 2024.</div></div><div><h3>Methods</h3><div>Demographic characteristics, baseline functional and OCT findings, treatment history, and outcomes at 12 months after switch to faricimab were extracted from the patients’ electronic case report forms.</div></div><div><h3>Main Outcome Measures</h3><div>Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals, and safety signals.</div></div><div><h3>Results</h3><div>Twelve months after switch, mean BCVA remained unchanged, whereas mean CST decreased from 315.3 to 263.9 μm (<em>P</em> < 0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (<em>r</em>(301) = 0.24; <em>P</em><span> < 0.01). After 12 months, 169 (47.9%) eyes demonstrated the absence of RF compared with 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, and extended treatment intervals (≥12 week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.</span></div></div><div><h3>Conclusions</h3><div>Switching to faricimab in pretreated nAMD led to sustained anatomic improvements and stabilization of BCVA, with a substantial reduction in RF compared with baseline. Our results suggest the potential benefits of this switching strategy based on real-world data.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Pages 838-847"},"PeriodicalIF":5.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Retina","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468653025001241","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pretreated neovascular age-related macular degeneration (nAMD).

Design

Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network.

Subjects

We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-VEGF therapy and followed for a minimum of 12 months between May 1, 2022, and October 30, 2024.

Methods

Demographic characteristics, baseline functional and OCT findings, treatment history, and outcomes at 12 months after switch to faricimab were extracted from the patients’ electronic case report forms.

Main Outcome Measures

Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals, and safety signals.

Results

Twelve months after switch, mean BCVA remained unchanged, whereas mean CST decreased from 315.3 to 263.9 μm (P < 0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (r(301) = 0.24; P < 0.01). After 12 months, 169 (47.9%) eyes demonstrated the absence of RF compared with 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, and extended treatment intervals (≥12 week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases.

Conclusions

Switching to faricimab in pretreated nAMD led to sustained anatomic improvements and stabilization of BCVA, with a substantial reduction in RF compared with baseline. Our results suggest the potential benefits of this switching strategy based on real-world data.

Financial Disclosure(s)

Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

查看原文本刊更多论文

一份瑞士视网膜研究网络报告：法利昔单抗治疗前新生血管性年龄相关性黄斑变性患者后一年的疗效

目的：报告在瑞士一个真实世界中预先接受治疗的新生血管性年龄相关性黄斑变性（nAMD）患者队列中改用法尼单抗的疗效和安全性：设计：在瑞士视网膜研究网络的 11 个中心进行的回顾性、多中心、纵向观察研究：我们纳入了325名患者的353只眼睛，这些患者在之前接受过抗血管内皮生长因子（anti-VEGF）治疗后转为使用玻璃体内法替单抗，并在2022年5月1日至2024年10月30日期间接受了至少12个月的随访：从患者的电子病例报告表中提取人口统计学特征、基线功能和光学相干断层扫描结果、治疗史以及转用法替单抗后12个月的结果：主要结果测量指标：最佳矫正视力（BCVA）、中央子野厚度（CST）、视网膜积液（RF）和色素上皮脱落、治疗间隔和安全信号的变化：结果：换药 12 个月后，平均 BCVA 保持不变，而平均 CST 则从 315.3 μm 降至 263.9 μm（p结论：在接受预处理的 nAMD 患者中改用法尼单抗治疗后，BCVA 的解剖结构得到持续改善并趋于稳定，RF 与基线相比大幅下降。我们的结果表明，基于真实世界的数据，这种转换策略具有潜在的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊